BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 36866590)

  • 1. Confidence intervals for prevalence estimates from complex surveys with imperfect assays.
    Bayer DM; Fay MP; Graubard BI
    Stat Med; 2023 May; 42(11):1822-1867. PubMed ID: 36866590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of SARS-CoV-2 Seroprevalence in Central North Carolina: Accounting for Outcome Misclassification in Complex Sample Designs.
    Vias NP; Cassidy CA; Edwards JK; Xiong K; Beatty Parker C; Aiello AE; Boyce RM; Shook-Sa BE
    Epidemiology; 2023 Sep; 34(5):721-731. PubMed ID: 37527450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
    Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
    Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.
    Angulo FJ; Finelli L; Swerdlow DL
    JAMA Netw Open; 2021 Jan; 4(1):e2033706. PubMed ID: 33399860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.
    Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM
    JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjusting COVID-19 Seroprevalence Survey Results to Account for Test Sensitivity and Specificity.
    Meyer MJ; Yan S; Schlageter S; Kraemer JD; Rosenberg ES; Stoto MA
    Am J Epidemiol; 2022 Mar; 191(4):681-688. PubMed ID: 34791024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study.
    Moshe M; Daunt A; Flower B; Simmons B; Brown JC; Frise R; Penn R; Kugathasan R; Petersen C; Stockmann H; Ashby D; Riley S; Atchison C; Taylor GP; Satkunarajah S; Naar L; Klaber R; Badhan A; Rosadas C; Marchesin F; Fernandez N; Sureda-Vives M; Cheeseman H; O'Hara J; Shattock R; Fontana G; Pallett SJC; Rayment M; Jones R; Moore LSP; Ashrafian H; Cherapanov P; Tedder R; McClure M; Ward H; Darzi A; Elliott P; Cooke GS; Barclay WS;
    BMJ; 2021 Mar; 372():n423. PubMed ID: 33653694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence.
    Miller CN; Althoff KN; Schlueter DJ; Anton-Culver H; Chen Q; Garbett S; Ratsimbazafy F; Thomsen I; Karlson EW; Cicek M; Pinto LA; Malin BA; Ohno-Machado L; Williams C; Goldstein D; Kouame A; Ramirez A; Gebo KA; Schully SD;
    mSphere; 2022 Oct; 7(5):e0025722. PubMed ID: 36173112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple approximation of sample size for precise estimates of SARS-CoV-2 infection from point-seroprevalence studies.
    Nikiforuk AM; Sekirov I; Jassem AN
    Public Health; 2022 Nov; 212():7-9. PubMed ID: 36174438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
    Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
    JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic.
    Palmateer NE; Dickson E; Furrie E; Godber I; Goldberg DJ; Gousias P; Jarvis L; Mathie L; Mavin S; McMenamin J; McNeilly TN; Murcia P; Murray J; Reid G; Robertson C; Templeton K; von Wissmann B; Wallace LA; Waugh C; McAuley A
    Public Health; 2021 Sep; 198():102-105. PubMed ID: 34411992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Over Time in 10 Sites in the United States, March-August, 2020.
    Lim T; Delorey M; Bestul N; Johannson MA; Reed C; Hall AJ; Fry AM; Edens C; Semenova V; Li H; Browning P; Desai R; Epperson M; Jia T; Thornburg NJ; Schiffer J; Havers FP
    Clin Infect Dis; 2021 Nov; 73(10):1831-1839. PubMed ID: 33639620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study.
    Mahajan S; Srinivasan R; Redlich CA; Huston SK; Anastasio KM; Cashman L; Massey DS; Dugan A; Witters D; Marlar J; Li SX; Lin Z; Hodge D; Chattopadhyay M; Adams MD; Lee C; Rao LV; Stewart C; Kuppusamy K; Ko AI; Krumholz HM
    Am J Med; 2021 Apr; 134(4):526-534.e11. PubMed ID: 33130124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies.
    Bergeri I; Whelan MG; Ware H; Subissi L; Nardone A; Lewis HC; Li Z; Ma X; Valenciano M; Cheng B; Al Ariqi L; Rashidian A; Okeibunor J; Azim T; Wijesinghe P; Le LV; Vaughan A; Pebody R; Vicari A; Yan T; Yanes-Lane M; Cao C; Clifton DA; Cheng MP; Papenburg J; Buckeridge D; Bobrovitz N; Arora RK; Van Kerkhove MD;
    PLoS Med; 2022 Nov; 19(11):e1004107. PubMed ID: 36355774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An international comparison of anti-SARS-COV-2 assays used for seroprevalence surveys from blood component providers.
    Lewin A; Drews SJ; Lieshout-Krikke R; Erikstrup C; Saeed S; Fady H; Uzicanin S; Custer B; O'Brien SF;
    Vox Sang; 2021 Oct; 116(9):946-954. PubMed ID: 33914918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population.
    Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R
    Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of SARS-CoV-2 Antibodies in New York City Adults, June-October 2020: A Population-Based Survey.
    Parrott JC; Maleki AN; Vassor VE; Osahan S; Hsin Y; Sanderson M; Fernandez S; Levanon Seligson A; Hughes S; Wu J; DeVito AK; LaVoie SP; Rakeman JL; Gould LH; Alroy KA
    J Infect Dis; 2021 Jul; 224(2):188-195. PubMed ID: 34086923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 transmission among children and staff in daycare centres during a nationwide lockdown in France: a cross-sectional, multicentre, seroprevalence study.
    Lachassinne E; de Pontual L; Caseris M; Lorrot M; Guilluy C; Naud A; Dommergues MA; Pinquier D; Wannepain E; Hausherr E; Jung C; Gajdos V; Cohen R; Zahar JR; Brichler S; Basmaci R; Boelle PY; Bloch-Queyrat C; Aupiais C;
    Lancet Child Adolesc Health; 2021 Apr; 5(4):256-264. PubMed ID: 33571450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies.
    Park Y; Hong KH; Lee SK; Hyun J; Oh EJ; Lee J; Lee H; Song SH; Kee SJ; Kwon GC; Kim SH; Do HN; Kim AR; Lee JW; Kim SS; Kim HS
    Ann Lab Med; 2022 Jan; 42(1):71-78. PubMed ID: 34374351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.